FTC Orders Boryung to Sell Cancer Drug Business in First Global M&A Remedy

Combination of No. 1 and No. 2 Players in Domestic Breast Cancer Treatment Market FTC Orders Pharmaceutical Firm Boryung to Sell Detaxel Business Monopoly Concerns Found in Sanofi's 'Taxotere' Acquisition Boryung Must Sell Detaxel Business Within Six Months First Remedial Action on a Korean Company's Overseas M&A

Finance|
|
By Kim Nam-myung
|

Content not available. Please visit the original article.

#Boryung#Sanofi#FTC#CancerDrug#Pharma#Antitrust#KoreaPharma

Original reporting by Kim Nam-myung for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

View Korean originalTranslation Policy
AI PRISM cover art

🎧Listen to AI PRISM·AI PRISM

Won Hits 17-Year Low, Jensen Huang Lands in Seoul, SpaceX IPO: Korea Macro Brief | June 05 2026

00:0005:48
← Back to Home

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Open in full screen

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

Open in full screen

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.

Open in full screen